Status:
COMPLETED
Norepinephrine Boluses in Liver Transplantation
Lead Sponsor:
Mansoura University
Conditions:
Living Donor Liver Transplantation
Norepinephrine Bolus
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
We study the efficacy of Norepinephrine boluses on prevention of postreperfusion syndrome during living donor liver transplantation. NE and Post-reperfusion: On portal vein declamping, we will start...
Detailed Description
Anesthesia technique: On admission to the pre-anesthetic room, patients will receive intravenous pantoprazole sodium 40 mg, midazolam 0.02 mg/kg and the prophylactic antibiotics. In the operating ro...
Eligibility Criteria
Inclusion
- All patients subjected to living donor liver transplantation with right lobe liver graft.
Exclusion
- Acute fulminant hepatitis
- Chronic hypertension
- Moderate to severe valvular heart disease
- Chronic kidney disease (CKD) and Hepatorenal syndrome (HRS)
- Preoperative S.Cr elevation \> 1.4 mg/kg or dialysis recently before surgery
- Long standing diabetes mellitus (\> 10 years on insulin)
- Moderate and sever Porto-pulmonary hypertension
- Moderate and sever Hepato-pulmonary syndrome (HPS)
- Contraindications to pulmonary artery catheter insertion
- Budd Chiari syndrome
- Re-transplantation
- Massive blood transfusion (more than 5 units of blood before portal clamping)
- Graft/weight ratio \> 1.4 and \< 0.8
Key Trial Info
Start Date :
December 17 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 28 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03773276
Start Date
December 17 2018
End Date
August 28 2020
Last Update
December 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University, Gastrointestinal Surgery Center, Liver Transplantation
Al Mansurah, Dakahlia Governorate, Egypt, 35516